Effects of Lithium Monotherapy for Bipolar Disorder on Gene Expression in Peripheral Lymphocytes.
Effects of Lithium Monotherapy for Bipolar Disorder on Gene Expression in Peripheral Lymphocytes.
复制标题
锂单药治疗双相情感障碍对外周淋巴细胞基因表达的影响。
DOI:
10.1159/000446348
复制
发表时间:
2016
期刊:
影响因子:
--
通讯作者:
Edenberg,HowardJ
中科院分区:
文献类型:
--
作者:
Anand,Amit;McClintick,JeanetteN;Murrell,Jill;Karne,Harish;Nurnberger,JohnI;Edenberg,HowardJ
Background:This study investigated the effect of lithium monotherapy on peripheral lymphocyte gene expression in bipolar disorder (BD).Method:Twenty-two medication-free bipolar subjects (11 hypomanic, 11 depressed) were started on lithium monotherapy. Closely matched healthy subjects (n = 15) were included as controls but did not receive treatment. Blood RNA samples were collected at baseline and after 2 and 8 weeks of treatment. RNA expression was measured using the Affymetrix GeneChip® Human Gene 1.0 ST Array followed by Ingenuity pathways analysis. The results for the contrast of weeks 2 and 8 were not significantly different and were combined.Results:In BD subjects, 56 genes showed significant (false discovery rate <0.1) expression changes from baseline; the effect sizes and directions for all of these were similar at weeks 2 and 8. Among these were immune-related genes (IL5RA, MOK, IFI6, and RFX2), purinergic receptors (P2RY14, P2RY2, and ADORA3) and signal transduction-related genes (CAMK1 and PIK3R6). Pathway and upstream regulator analysis also revealed that lithium altered several immune- and signal transduction-related functions. Differentially expressed genes did not correlate with week 8 clinical response, but other genes involved in protein synthesis and degradation did.Conclusion:Peripheral gene expression may serve as a biomarker of lithium effect.